Logo
x

Search

Subscribe Now

Prostate cancer

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

  • May 24, 2024
PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affa...

  • July 13, 2021
Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

  • May 27, 2021
PharmaShots Interview: Myriad Genetics' Dr. Todd D. Cohen Shares Insight on Prolaris Test's Ability to Guide Prostate Cancer Treatment

PharmaShots Interview: Myriad Genetics' Dr. Todd D. Cohen Shares Insight on Prolaris Test's Ability to Guide Prostate Cancer Treat...

  • March 25, 2021
The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

  • December 1, 2020
Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

  • January 30, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.